Clinical Trial Update: Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Safety study of BMX-001, a radioprotective agent, in patients with newly diagnosed anal cancer conducted in Phase 1/2; the trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Drugs mentioned

• BMX-001

Snippet

Sponsor: University of Nebraska | Conditions: Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING